Bill > HSB50

This Study Bill aims to make prescription insulin drugs more affordable for individuals with diabetes by requiring insurance plans to cap out-of-pocket expenses. Specifically, it mandates that insurance policies, contracts, or plans that cover prescription drugs must limit the "cost-sharing" – which includes copayments, coinsurance, deductibles, and other patient expenses – to no more than $100 for a 31-day supply of at least one type of rapid-acting, short-acting, intermediate-acting, and long-acting insulin. This provision applies to various types of health insurance, including individual and group accident and sickness insurance, hospital or medical service contracts, health maintenance organization contracts, and plans for public employees, and will take effect for policies renewed or issued on or after January 1, 2022.